Physician profile
Anna Ahn
NPI 1700105533
$3,937.19
in general payments reported to CMS, 2019-2025
33 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $214 · 2021: $153 · 2022: $473 · 2023: $698 · 2024: $788 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.87 |
| Education | $240.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $720.43 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $605.96 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.16 | 2019-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $278.93 | 2022-2025 | |
| Genzyme Corporation | $247.86 | 2019-2025 | |
| Harmony Biosciences LLC | $221.21 | 2023-2024 | Wakix |
| Mylan Specialty L.P. | $187.34 | 2019-2024 | Yupelri |
| Insmed, INC. | $156.15 | 2019-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $124.15 | 2020-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $93.97 | 2022-2024 | Acthar |
| United Therapeutics Corporation | $73.99 | 2019-2023 | Tyvaso |
| Baxter Healthcare | $72.78 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $70.69 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $67.96 | 2019-2020 | |
| Grifols USA, LLC | $65.87 | 2019-2025 | Prolastin-C Liquid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.40 | 2022-2025 | Tezspire |
| Fisher & Paykel Healthcare INC | $61.20 | 2019-2024 | Fisher & Paykel Healthcare |
| Electromed, INC. | $55.19 | 2019-2024 | Smartvest |
| Genentech USA, INC. | $55.10 | 2019-2023 | Xolair |
| Janssen Pharmaceuticals, INC | $53.57 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $52.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.12 | 2019 | |
| Merck Sharp & Dohme LLC | $40.78 | 2019-2025 | Keytruda |
| Philips North America LLC | $29.31 | 2019 | |
| Shire North American Group INC | $28.07 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.20 | 2019-2020 | |
| Verona Pharma, INC. | $25.79 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $23.28 | 2025 | Zemaira |
| Allergan, INC. | $21.76 | 2019 | |
| Axsome Therapeutics, INC. | $18.85 | 2025 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2020 | |
| Pulmonx Corporation | $17.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.